Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Reluscovtogene Ralaplasmid (INO-4800) | Coronavirus Infection | Phase 2/3 · NCT04642638 | Terminated |
| Bizalimogene Ralaplasmid (VGX-3100) | Cervical Dysplasia | Phase 3 · NCT03721978 | Completed |
| DNA Plasmid-encoding Interleukin-12/HPV DNA… | Uterine Cervical Neoplasms | Phase 2 · NCT02501278 | Withdrawn |
| HPV6/11-targeted DNA Plasmid Vaccine INO-3107 | Respiratory Papillomatosis | Phase 1/2 · NCT04398433 | Completed |
| p.DOM-WT1-37 DNA Vaccine | Leukaemia (Acute) | Phase 2 · NCT01334060 | Completed |
| Human Immunodeficiency Virus DNA | HIV-1-infection | Phase 1/2 · NCT03606213 | Completed |
| Imiquimod 5% Cream | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 · NCT03180684 | Completed |
| Rocakinogene Sifuplasmid (INO-9012) | Glioblastoma | Phase 1/2 · NCT03491683 | Active not recruiting |
| GLS-5300 | Healthy | Phase 1/2 · NCT03721718 | Completed |
| WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 | Glioblastoma | Phase 1/2 · NCT03491683 | Active not recruiting |
| Cisplatin chemotherapy | Uterine Cervical Neoplasms | Phase 2 · NCT02501278 | Withdrawn |
| INO-4700 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Phase 2 · NCT04588428 | Completed |
| INO-4500 | Lassa Fever | Phase 1 · NCT04093076 | Completed |
| INO-9112 | Coronavirus Infection | Phase 1 · NCT05430958 | Withdrawn |
| DNA Plasmid-encoding Interleukin-12… | Metastatic Castration-resistant Prostate Cancer | Phase 1 · NCT03835533 | Completed |
| INO-A002 | Healthy Volunteers | Phase 1 · NCT03831503 | Completed |
Also used in these trials (approved or third-party drugs, not INO's own candidates): Temozolomide, Cemiplimab, Atezolizumab, Nivolumab, Poly ICLC, Alum.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INO had $48.4M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $139.8M pro forma, before operating spending after that date:
It burns about $16.7M/quarter from operations, an estimated runway of 25.2 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 60 · High
In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2027.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | Institution (13G, 5%+) | 25,288,217 | 13.50% | 2026-09-30 |
| TANG CAPITAL MANAGEMENT, LLC | 5%+ holder (13G) | 17,978,200 | 9.60% | 2026-11-06 |
| FMR LLC | Institution (13G, 5%+) | 15,364,105 | 8.20% | 2026-09-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 10,666,523 | 5.69% | 2026-07-31 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 6,666,295 | 3.56% | 2025-11-28 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 6,429,624 | 3.43% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,161,566 | 2.22% | 2026-06-30 |
| Citadel Advisors Llc | Institution (13F) | 3,126,541 | 1.67% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 2,539,360 | 1.36% | 2026-09-30 |
| Shaw D.E. & Co., Inc. | Institution (13F) | 2,468,480 | 1.32% | 2026-09-30 |
| Marshall Wace LLP | Institution (13F) | 2,279,039 | 1.22% | 2026-09-30 |
| Renaissance Technologies, LLC | Institution (13F) | 1,513,187 | 0.81% | 2026-09-30 |
Share count 187,306,884 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-05-20 filed 2026-05-21 |
BENITO SIMON X |
Option award (A) | 41,800 | – | – |
| 2026-05-20 filed 2026-05-21 |
DANSEY ROGER D |
Option award (A) | 41,800 | – | – |
| 2026-05-20 filed 2026-05-21 |
Weiner David B. |
Option award (A) | 34,200 | – | – |
| 2026-05-20 filed 2026-05-21 |
Weiner David B. |
Option award (A) | 41,800 | – | – |
| 2026-05-20 filed 2026-05-21 |
Shepard Jay |
Option award (A) | 34,200 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-10-30 | VOCERYQ | BLA | -36.9% | -22.1% | — |
| 2025-05-13 | — | BLA | +22.8% | -1% | +6.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →